OMGAQ (Omega Therapeutics) EBIT: $-74.15 Mil (TTM As of Sep. 2024)

What is Omega Therapeutics EBIT?

Omega Therapeutics OMGAQ +50.00% 16 EBIT is $-74.15 Mil as of Sep. 2024. GuruFocus rates OMGAQ with a GF Score™ of 16/100.

Omega Therapeutics's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2024 was $-16.42 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2024 was $-74.15 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Omega Therapeutics's annualized ROC % for the quarter that ended in Sep. 2024 was -48.89%. Omega Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was -58.16%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Omega Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was -75.72%.

Omega Therapeutics (OTCPK:OMGAQ) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Omega Therapeutics's annualized ROC % for the quarter that ended in Sep. 2024 is calculated as:

	ROC % (Q: Sep. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2024 )	+	Invested Capital (Q: Sep. 2024 ))	/ count )
=	-65.68 * ( 1 - 0% )	/	( (134.134	+	134.527)	/ 2 )
=	-65.68	/	134.3305
=	-48.89 %

where

	Invested Capital		(Q: Jun. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	168.225	-	3.571	-	( 45.852	-	max(0, 25.543	-	56.063	+	45.852	))
=	134.134

	Invested Capital		(Q: Sep. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	152.727	-	3.42	-	( 30.377	-	max(0, 24.173	-	38.953	+	30.377	))
=	134.527

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Omega Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Sep. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2024		Q: Sep. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-65.68	/	( ( (112.111 + max(-0.25699999999999, 0))	+	(113.743 + max(-0.641, 0)) )	/	2 )
=	-65.68	/	( ( 112.111	+	113.743 )	/	2 )
=	-65.68	/	112.927
=	-58.16 %

where Working Capital is:

	Working Capital		(Q: Jun. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	9.458)	-	(3.571	+	0	+	6.144)
=	-0.25699999999999

	Working Capital		(Q: Sep. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	7.613)	-	(3.42	+	0	+	4.834)
=	-0.641

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Omega Therapeutics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Sep. 2024 )
	=	-74.15	/	97.922
	=	-75.72 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Omega Therapeutics EBIT Related Terms

Omega Therapeutics EBIT Historical Data

* Premium members only.

The historical data trend for Omega Therapeutics's EBIT can be seen below:

Omega Therapeutics EBIT Chart

Omega Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

-17.35

-28.67

-66.03

-102.77

-100.26

Omega Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EBIT	Get a 7-Day Free Trial															-22.90	-20.70	-20.45	-16.58	-16.42

OMGAQ vs ENDV, ORGS, PBLA: EBIT Comparison

For the Biotechnology subindustry, Omega Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Omega Therapeutics EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Omega Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Omega Therapeutics's EV-to-EBIT falls into.

Save Embed

16GF Score

Omega Therapeutics Inc OMGAQ

EBIT is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Omega Therapeutics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-74.15 Mil.

Frequently Asked Questions Learn more about EBIT →

What does a EBIT of $-74.15 Mil mean?

Omega Therapeutics (OMGAQ) has a EBIT of $-74.15 Mil as of Sep. 2024. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Omega Therapeutics.

Is Omega Therapeutics' EBIT too high?

Omega Therapeutics' current EBIT is $-74.15 Mil. Overall, Omega Therapeutics has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.

How does Omega Therapeutics' EBIT compare to ENDV and ORGS?

Omega Therapeutics' EBIT of $-74.15 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBIT for a Biotechnology company?

A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBIT mean?

A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Omega Therapeutics. Omega Therapeutics's current EBIT is $-74.15 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Omega Therapeutics stock overvalued right now?

Omega Therapeutics (OMGAQ) has a current EBIT of $-74.15 Mil. The current EBIT is $-74.15 Mil. Omega Therapeutics' overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBIT calculated?

EBIT is calculated from a company's financial statements. For Omega Therapeutics (OMGAQ), the current EBIT is $-74.15 Mil as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Omega Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies ENDV ORGS PBLA GBLX VINC VRPX CNBX KRBPQ HSTC TRVN VRTX ASX:CSL REGN ALNY XKRX:207940 XBRU:ARGX XBRU:UCB ONC INSM XKRX:068270

Address 140 First Street, Suite 501, Cambridge, MA, USA, 02141

Website https://www.omegatherapeutics.com

Omega Therapeutics Inc is a development-stage biotechnology company leveraging its proprietary epigenomic programming platform to biologically engineer a new class of programmable epigenetic medicines, known as Omega Epigenomic Controllers. Using epigenomic controllers, Omega is seeking to transform the practice of human medicine through selective and direct control of the human genome to treat and cure disease. It operates in the U.S.

16GF Score

Get the complete analysis for OMGAQ

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00

Price

View OMGAQ Analysis

See EBIT data for all stocks →